|
Synonyms: ALXN-1720 | ALXN1720 | CON-9978 | Klygefa® | TPP-2511
Compound class:
Antibody
Comment: Gefurulimab (ALXN1720) is a bispecific VHH nanobody that binds complement component C5 (in the terminal complement cascade) and serum albumin [1]. It is designed to block enzymatic cleavage of C5 (into biologically active C5a and C5b fragments), and reduce inflammation. Binding to serum albumin extends the agent's systemic half-life and therapeutic window.
|
| Bioactivity Comments |
| Gefurulimab (ALXN1720) binds human serum albumin with Kd 0.9 nM [1]. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||